Changes of blood pressure, abdominal visceral fat tissue and gene expressions in fetal programming induced rat model after amlodipine–losartan combination treatment

Table 3 Changes of serum lipid profile in fetal programming model after amlodipine-losartan combination treatment

Week		Blood sugar (mg/dL)	TG (mg/dL)	TC (mg/dL)	HDL-C (mg/dL)	LDL-C (mg/dL)
4	C	288.50 ± 142.13	107.50 ± 62.98	84.33 ± 3.06	65.33 ± 11.93	18.00 ± 6.08
	FR	237.00 ± 108.43	142.00 ± 47.76	82.67 ± 2.52	66.67 ± 0.87	16.00 ± 4.58
	CX	205.00 ± 0.00	83.00 ± 2.83	76.50 ± 2.12	65.50 ± 0.72	18.00 ± 0.00
8	C	202.00 ± 14.72	45.75 ± 14.24	43.00 ± 6.78	40.50 ± 6.24	4.50 ± 1.00
	FR	207.50 ± 58.34	145.50 ± 26.80*	62.75 ± 8.34	56.75 ± 0.85	7.50 ± 1.73
	CX	263.00 ± 25.87	105.50 ± 28.63	62.75 ± 7.04	57.50 ± 5.45	9.25 ± 1.89
12	C	127.75 ± 10.21	20.25 ± 10.31	42.25 ± 3.40	42.25 ± 2.99	5.75 ± 1.26
	FR	101.00 ± 18.17	38.25 ± 7.50*	41.50 ± 7.59	42.00 ± 6.68	5.00 ± 2.16
	CX	165.00 ± 94.69	30.00 ± 8.54	37.25 ± 22.51	37.00 ± 14.72	4.25 ± 3.86
16	C	169.33 ± 3.33	62.50 ± 14.50	60.50 ± 12.82	52.00 ± 10.39	4.67 ± 0.47
	FR	189.50 ± 11.32	81.50 ± 0.32	54.25 ± 6.54	48.50 ± 12.84	5.00 ± 2.74
	CX	191.67 ± 39.14	86.25 ± 32.93	54.50 ± 7.09	445.75 ± 4.44	5.00 ± 0.82
20	C	141.17 ± 36.99	33.20 ± 13.31	48.50 ± 10.88	45.17 ± 9.70	5.33 ± 2.42
	FR	195.00 ± 22.58	76.80 ± 13.03*	63.71 ± 17.74	56.71 ± 16.54	6.17 ± 3.29
	CX	181.00 ± 19.61	42.75 ± 10.34†	68.00 ± 24.99	63.40 ± 2.48	8.20 ± 3.49

C control, FR food restriction, CX amlodipine losartan-combination, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol
*C group vs FR group, p <0.05, † FR group vs CX group, p <0.05

ISSN: 2056-5909